Benitec Biopharma (ASX:BLT) has entered into an agreement with Maryland-based Omnia Biologics to manufacture material for its current first-in-man clinical trial for its TT-034 hepatitis C treatment.
This ensures the company has enough clinical material to complete the current trial.
The company is also moving to establish its own scalable manufacturing process in collaboration with third parties to supply large markets it is targeting.
Hepatitis C Treatment
TT-034 is a ddRNAi-based therapeutic that is designed to treat and potentially cure hepatitis C with a single administration.
It targets the hepatitis C viral RNA at three separate, highly conserved sites, which minimises the ability of the virus to mutate and escape the therapy.
Once it reaches the liver cells, it enters the nucleus and produces three separate short hairpin RNAs continuously for the live of the cell.
This has the potential to guard against reinfection for months to years without the need to re-treat.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.